全文获取类型
收费全文 | 2808篇 |
免费 | 179篇 |
国内免费 | 60篇 |
学科分类
医药卫生 | 3047篇 |
出版年
2023年 | 38篇 |
2022年 | 98篇 |
2021年 | 110篇 |
2020年 | 78篇 |
2019年 | 64篇 |
2018年 | 83篇 |
2017年 | 68篇 |
2016年 | 81篇 |
2015年 | 78篇 |
2014年 | 195篇 |
2013年 | 156篇 |
2012年 | 133篇 |
2011年 | 150篇 |
2010年 | 176篇 |
2009年 | 162篇 |
2008年 | 147篇 |
2007年 | 161篇 |
2006年 | 123篇 |
2005年 | 113篇 |
2004年 | 112篇 |
2003年 | 85篇 |
2002年 | 77篇 |
2001年 | 66篇 |
2000年 | 65篇 |
1999年 | 62篇 |
1998年 | 30篇 |
1997年 | 36篇 |
1996年 | 26篇 |
1995年 | 27篇 |
1994年 | 37篇 |
1993年 | 14篇 |
1992年 | 25篇 |
1991年 | 23篇 |
1990年 | 14篇 |
1989年 | 23篇 |
1988年 | 12篇 |
1987年 | 10篇 |
1986年 | 8篇 |
1985年 | 15篇 |
1984年 | 19篇 |
1983年 | 5篇 |
1982年 | 8篇 |
1981年 | 10篇 |
1980年 | 5篇 |
1978年 | 5篇 |
1977年 | 6篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1906年 | 1篇 |
排序方式: 共有3047条查询结果,搜索用时 203 毫秒
51.
Franchini M Montagnana M Targher G Manzato F Lippi G 《Journal of thrombosis and thrombolysis》2007,24(1):29-38
The relationship between increased clotting and malignancy is well recognized, though the bidirectional development of this association is often overlooked. In the challenging cancer biology, transforming genes often act in concert with numerous epigenetic factors, including hypoxia, inflammation, contact between blood and cancer cells, and emission of procoagulant vesicles from tumors, to determine a net imbalance of the hemostatic potential which is detectable by a variety of laboratory tests. Procoagulant factors, in particular, are intimately involved in all aspects of hemostatic, cell proliferation and cellular signalling systems. However, the biggest as yet unresolved question is why cancer patients develop thrombosis? Since the thrombus itself does not apparently contributes directly to the tumor biology, enhanced hemostasis activation in cancer patients may be interpreted according to the most recent biological evidences. Coagulation and cancer biology interact bidirectionally in a “vicious cycle”, in which greater tumor burden supplies greater procoagulants (tissue factor, cancer procoagulant) and thrombin, which would in turn act as strong promoters of cancer growth and spread. In this perspective, thrombosis may be interpreted as a epiphenomenon of an intricate an effective biological feedback to maintain or promote cancer progression. In this review article, we briefly analyze the pathogenesis, laboratory, clinical and therapeutic features of cancer and thrombosis. 相似文献
52.
摘 要 目的: 研究肝素联合低分子肝素对预防动静脉内瘘(AVF)术后早期血栓形成的影响。方法: 采用前瞻性研究方法,将299例行AVF术的患者随机分为两组,对照组患者术后给予低分子肝素5 000 IU皮下注射qd×7 d;观察组术中在游离动脉端与静脉端分别推注1 500 u肝素钠,术后给予低分子肝素5 000 IU皮下注射qd×7 d。观察两组患者术后1周和4周AVF血栓形成率及药品不良反应(ADR)发生情况。结果: 术后1周,对照组和观察组的AVF血栓形成率分别为3.4%和0;术后4周分别为4.8%和0.67%,观察组均明显低于对照组(P<0.05)。两组ADR发生率差异无统计学意义(P>0.05),未发生严重不良反应。结论: 肝素联合低分子肝素可降低AVF术后早期血栓形成率,提高手术成功率,安全性较好。 相似文献
53.
Yukiko Hasuike Naoto Kakita Makoto Aichi Satoko Masachika Mari Kantou Shoko Ikeda Takahashi Masayoshi Nanami Yasuyuki Nagasawa Takahiro Kuragano Takeshi Nakanishi 《Journal of vascular surgery》2019,69(1):174-180.e2
Objective
For patients with end-stage renal disease on hemodialysis, the durability of vascular access (VA) is still far from optimal, and access survival after intervention for access failure is an important aspect. Procoagulant status is a leading cause of access failure. Coagulation-fibrinolysis imbalance can occur in hemodialyzed patients, but the influence of the imbalance has not been fully elucidated.Methods
We prospectively examined coagulation-fibrinolysis balance to assess the risk of access failure after the intervention of revascularization in a cohort of 462 hemodialysis patients. Thrombin-antithrombin complex (TAT) and plasmin-α2-plasmin inhibitor complex (PIC) are markers for coagulation and fibrinolysis. Median follow-up was 243 days. The end point was clinical access failure: revascularization or access revision. The survival curve for VA patency was assessed using the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazards regression models that allowed adjustment for baseline differences in age, sex, dialysis vintage, diabetes mellitus, and various factors (quantity of blood flow, prothrombin time-international normalized ratio, fibrin degradation products, C-reactive protein, interleukin-6, tumor necrosis factor-α, and pentraxin-3) were used.Results
The 162 patients who reached an end point had smaller access flow volume and smaller percentage of arteriovenous fistula and higher TAT/PIC ratio. Kaplan-Meier analysis indicated that the patients with elevated TAT/PIC ratio showed poorer outcome (P < .001). On Cox regression modeling, elevated TAT/PIC was an independent risk factor for access failure (hazard ratio, 1.58; P = .03).Conclusions
Our results suggest that coagulation-fibrinolysis imbalance is a significant risk factor for access failure and may predict VA failure in hemodialyzed patients after access intervention. 相似文献54.
Direct oral anticoagulants (DOACs) are small molecule inhibitors of the coagulation proteases thrombin and factor Xa that demonstrate comparable efficacy to warfarin for several common indications, while causing less serious bleeding. However, because their targets are required for the normal host-response to bleeding (hemostasis), DOACs are associated with therapy-induced bleeding that limits their use in certain patient populations and clinical situations. The plasma contact factors (factor XII, factor XI, and prekallikrein) initiate blood coagulation in the activated partial thromboplastin time assay. While serving limited roles in hemostasis, pre-clinical and epidemiologic data indicate that these proteins contribute to pathologic coagulation. It is anticipated that drugs targeting the contact factors will reduce risk of thrombosis with minimal impact on hemostasis. Here, we discuss the biochemistry of contact activation, the contributions of contact factors in thrombosis, and novel antithrombotic agents targeting contact factors that are undergoing pre-clinical and early clinical testing. 相似文献
55.
56.
57.
《Clinical and experimental hypertension (New York, N.Y. : 1993)》2013,35(7-8):603-610
The benefit of antiplatelet therapy remains unclear, although it does appear that aspirin monotherapy started within 48 hours of stroke onset may result in a modest clinical improvement. Glicoprotein (GP) IIb/IIIa antagonists are currently considered the most powerful specific inhibitors of platelet activation in acute thrombosis. Glicoprotein IIb/IIIa inhibitor therapy could merit a prominent role also in the initial management of patients with acute ischemic stroke. Abciximab may be promising in this setting and should be evaluated in further clinical trials. 相似文献
58.
《Current medical research and opinion》2013,29(4):271-273
SummaryA double-blind, placebo-controlled crossover study oj the effect of sulphinpyrazone on blood viscosity and its determinants (haematocrit, plasma fibrinogen and plasma viscosity) was carried out in 7 healthy male volunteers. Apart from a transient rise in fibrinogen (p<0.05) after 3 days of sulphinpyrazone treatment, no significant change in viscosity factors was seen over a 14-day period. 相似文献
59.
60.
目的:在肠系膜上静脉血栓治疗过程中,超声用于评价疗效和指导治疗的价值。方法:肠系膜上静脉血栓住院治疗的8例患者,超声连续观察肠系膜上静脉内径,血栓回声;肠系膜上动脉血流速度及阻力指数;水肿肠管的长度,肠壁厚度;周围小血管情况;腹腔积液的量等指标,评价治疗效果,指导临床。结果:8例肠系膜上静脉血栓的患者,根据临床资料,结合超声指征,3例手术治疗,其中1例术后第2天死亡,其余术后症状明显缓解,超声呈逐渐恢复表现。5例保守治疗,超声征象改善,症状逐步缓解,出院。结论:超声实时、动态观察肠系膜上静脉血栓治疗中的声像图变化,及时评价治疗效果,为临床提供直接证据,指导治疗。 相似文献